CO6351778A2 - Acidos naftilaceticos - Google Patents

Acidos naftilaceticos

Info

Publication number
CO6351778A2
CO6351778A2 CO11036992A CO11036992A CO6351778A2 CO 6351778 A2 CO6351778 A2 CO 6351778A2 CO 11036992 A CO11036992 A CO 11036992A CO 11036992 A CO11036992 A CO 11036992A CO 6351778 A2 CO6351778 A2 CO 6351778A2
Authority
CO
Colombia
Prior art keywords
compounds
formula
naftilacetic
acids
receptor
Prior art date
Application number
CO11036992A
Other languages
English (en)
Inventor
Li Chen
Fariborz Firooznia
Paul Gillespie
Yun He
Tai-An Lin
Eric Mertz
Sung-Sau So
Hong Yun
Zhenshan Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO6351778A2 publication Critical patent/CO6351778A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos de la fórmula I:y a sales y ésteres farmacéuticamente aceptables de los mismos, en el que W, X, Y y R1-R7 tienen los significadosdefinidos en la descripción detallada y en las reivindicaciones, Además, la presente invención se refiere a métodos de obtención y uso de los compuestos de la fórmula I así como a composiciones farmacéuticas que contienen tales compuestos.Los compuestos de la fórmula I son antagonistas o agonistas parciales del receptor CRTH2 y pueden ser útiles para tratar enfermedades y trastornos asociados con este receptor, por ejemplo el asma.
CO11036992A 2008-11-17 2011-03-25 Acidos naftilaceticos CO6351778A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11513308P 2008-11-17 2008-11-17
US22218209P 2009-07-01 2009-07-01

Publications (1)

Publication Number Publication Date
CO6351778A2 true CO6351778A2 (es) 2011-12-20

Family

ID=41467025

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11036992A CO6351778A2 (es) 2008-11-17 2011-03-25 Acidos naftilaceticos

Country Status (30)

Country Link
US (1) US8642629B2 (es)
EP (1) EP2346819B1 (es)
JP (1) JP5463365B2 (es)
KR (1) KR101322496B1 (es)
CN (1) CN102216265B (es)
AR (1) AR074352A1 (es)
AU (1) AU2009315712A1 (es)
BR (1) BRPI0921038A2 (es)
CA (1) CA2740863A1 (es)
CO (1) CO6351778A2 (es)
CR (1) CR20110219A (es)
CY (1) CY1114200T1 (es)
DK (1) DK2346819T3 (es)
EC (1) ECSP11011057A (es)
ES (1) ES2408963T3 (es)
HK (1) HK1162461A1 (es)
HR (1) HRP20130613T1 (es)
IL (1) IL212077A0 (es)
MA (1) MA32798B1 (es)
MX (1) MX2011005120A (es)
NZ (1) NZ591914A (es)
PE (1) PE20110703A1 (es)
PL (1) PL2346819T3 (es)
PT (1) PT2346819E (es)
RS (1) RS52809B (es)
RU (1) RU2539185C2 (es)
SG (1) SG171734A1 (es)
TW (1) TWI377197B (es)
WO (1) WO2010055004A1 (es)
ZA (1) ZA201102524B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2728311A1 (en) 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Aminotetrahydroindazoloacetic acids
EP2307383B1 (en) 2008-07-15 2012-05-16 F. Hoffmann-La Roche AG Aminotetrahydroindazoloacetic acids
AU2009315713A1 (en) 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Naphthylacetic acids
WO2010055006A1 (en) * 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Naphthylacetic acids used as crth2 antagonists or partial agonists
RU2013104506A (ru) 2010-07-05 2014-08-10 Актелион Фармасьютиклз Лтд 1-фенилзамещенные производные гетероциклила и их применение в качестве модуляторов рецептора простагландина d2
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US8470884B2 (en) * 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
US8691993B2 (en) * 2011-12-12 2014-04-08 Hoffmann-La Roche Inc. Piperidinyl naphthylacetic acids
ES2624379T3 (es) 2011-12-21 2017-07-14 Idorsia Pharmaceuticals Ltd Derivados de heterociclilo y su uso como moduladores del receptor de prostaglandina D2
US9000044B2 (en) * 2012-02-28 2015-04-07 Hoffmann-La Roche Inc. Substituted naphthylacetic acids
JP6127135B2 (ja) 2012-07-05 2017-05-10 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−フェニル置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
EP3286187B1 (en) 2015-04-24 2019-09-18 Syngenta Participations AG Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocyles
CA3049720A1 (en) 2017-01-09 2018-07-12 The Children's Hospital Of Philadelphia Compositions and methods targeting the th2 pathway for the treatment of asthma
CN118786122A (zh) * 2022-03-01 2024-10-15 先正达农作物保护股份公司 基于嘧啶基-氧基-喹啉的除草化合物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899529A (en) * 1973-02-22 1975-08-12 Merck & Co Inc Aroyl substituted naphthalene acetic acids
US4443462A (en) 1979-08-06 1984-04-17 Merrell Dow Pharmaceuticals Inc. Antipsychotic 4-(naphthalenyloxy)piperidine derivatives
US4371537A (en) * 1981-08-13 1983-02-01 The Dow Chemical Company Sulfur-substituted phenoxypyridines having antiviral activity
DE3631824A1 (de) 1986-02-21 1988-03-31 Bayer Ag Cycloalkano(1.2-b)indol-sulfonamide
DE3623941A1 (de) * 1986-07-16 1988-01-28 Bayer Ag Substituierte amino-5,6,7,8-tetrahydronaphthyl-oxyessigsaeuren, verfahren zu deren herstellung sowie die verwendung als arzneimittel
EP0405602A1 (en) 1989-06-30 1991-01-02 Laboratorios Vinas S.A. New Zinc derivatives of anti-inflammatory drugs having improved therapeutic activity
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
DE4235155A1 (de) * 1992-10-19 1994-04-21 Basf Ag Verfahren zur Herstellung von Methylsulfonylbenzoesäuren
JP2562405B2 (ja) 1993-04-06 1996-12-11 花王株式会社 ケラチン繊維処理剤組成物
DK0657422T3 (da) 1993-12-09 1998-10-12 Ono Pharmaceutical Co Naphthyloxyeddikesyrederivater som PEG2-agonister og -antagonister
GB9516788D0 (en) 1995-08-16 1995-10-18 Agrevo Uk Ltd Fungicides
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
GB0028702D0 (en) * 2000-11-24 2001-01-10 Novartis Ag Organic compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
MXPA05006701A (es) 2002-12-20 2006-03-30 Amgen Inc Moduladores de asma y de inflacion alergica.
US20070161698A1 (en) * 2003-05-30 2007-07-12 Microbia, Inc. Modulators of CRTH2 Activity
ATE388708T1 (de) * 2003-06-20 2008-03-15 Amgen Inc Piperazinderivate und anwendungsverfahren
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
AU2004283139A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds having CRTH2 antagonist activity
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7226951B2 (en) * 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
BRPI0515522A (pt) 2004-09-21 2008-07-29 Athersys Inc composto, composição farmacêutica. métodos de inibir a ligação de ligandos endógenos ao receptor crth-2 em uma célula, de tratar, melhorar ou prevenir um distúrbio responsivo à inibição da ligação de ligandos endógenos ao receptor crth-2 em um animal e de preparar um composto, e, kit
EP1799637A1 (en) 2004-09-23 2007-06-27 Amgen, Inc Substituted sulfonamidopropionamides and methods of use
WO2006032466A2 (en) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
ES2314749T3 (es) * 2004-12-21 2009-03-16 F. Hoffmann-La Roche Ag Derivados de tetralina y de indano y usos de los mismos como antagonistas de 5-ht.
WO2006091674A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
JP5249031B2 (ja) 2005-09-01 2013-07-31 イーライ リリー アンド カンパニー ５−ＨＴ２Ｃ受容体アゴニストとしての６−Ｎ結合型へテロ環置換された２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
KR101289995B1 (ko) 2005-09-27 2013-07-26 시오노기 앤드 컴파니, 리미티드 Ｐｇｄ2 수용체 길항제 활성을 갖는 설폰아마이드 유도체
CN101273013B (zh) * 2005-09-27 2013-06-12 盐野义制药株式会社 具有pgd2受体拮抗活性的磺酰胺衍生物
KR101409261B1 (ko) 2006-05-26 2014-06-18 다이쇼 세이야꾸 가부시끼가이샤 신규의 복소환 화합물 또는 그 염 및 그 중간체
CA2653903A1 (en) 2006-06-12 2007-12-21 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
BRPI0714554A2 (pt) * 2006-07-25 2013-05-07 Sanofi Aventis 2-fenil-indàis como antagonistas do receptor de prostaglandina d2
CL2007003693A1 (es) 2006-12-22 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
EP2307383B1 (en) * 2008-07-15 2012-05-16 F. Hoffmann-La Roche AG Aminotetrahydroindazoloacetic acids
CA2728311A1 (en) * 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Aminotetrahydroindazoloacetic acids
CN102066317A (zh) * 2008-08-15 2011-05-18 霍夫曼-拉罗奇有限公司 取代的氨基四氢化萘
WO2010018112A2 (en) * 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Monoaryl aminotetralines
EP2321268A2 (en) * 2008-08-15 2011-05-18 F. Hoffmann-La Roche AG Bi-aryl aminotetralines
AU2009315713A1 (en) * 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Naphthylacetic acids
WO2010055006A1 (en) * 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Naphthylacetic acids used as crth2 antagonists or partial agonists

Also Published As

Publication number Publication date
HK1162461A1 (en) 2012-08-31
PE20110703A1 (es) 2011-10-13
MX2011005120A (es) 2011-05-30
EP2346819B1 (en) 2013-04-10
US20100125058A1 (en) 2010-05-20
NZ591914A (en) 2013-04-26
PL2346819T3 (pl) 2013-09-30
MA32798B1 (fr) 2011-11-01
RU2011124150A (ru) 2012-12-27
KR101322496B1 (ko) 2013-10-29
US8642629B2 (en) 2014-02-04
CY1114200T1 (el) 2016-08-31
RS52809B (en) 2013-10-31
SG171734A1 (en) 2011-07-28
CR20110219A (es) 2011-08-24
AU2009315712A1 (en) 2010-05-20
CA2740863A1 (en) 2010-05-20
JP5463365B2 (ja) 2014-04-09
HRP20130613T1 (en) 2013-07-31
RU2539185C2 (ru) 2015-01-20
IL212077A0 (en) 2011-06-30
EP2346819A1 (en) 2011-07-27
TWI377197B (en) 2012-11-21
KR20110071121A (ko) 2011-06-28
ES2408963T3 (es) 2013-06-24
JP2012508714A (ja) 2012-04-12
TW201022207A (en) 2010-06-16
WO2010055004A1 (en) 2010-05-20
AR074352A1 (es) 2011-01-12
CN102216265A (zh) 2011-10-12
CN102216265B (zh) 2014-04-30
PT2346819E (pt) 2013-05-10
ZA201102524B (en) 2014-09-25
DK2346819T3 (da) 2013-05-13
BRPI0921038A2 (pt) 2019-09-24
ECSP11011057A (es) 2011-10-31

Similar Documents

Publication Publication Date Title
CO6351778A2 (es) Acidos naftilaceticos
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
CL2019002103A1 (es) Derivados de tirosinamida como inhibidores de rho-quinasa.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
HN2012001744A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
CO6630147A2 (es) Modificador del sabor dulce
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
CO6290683A2 (es) Compuestos de pirido imidazolinas heterociclicas y sus composiciones como inhibidores de c-met
CO6290662A2 (es) Derivados de amidas espirociclicas para el tratamiento de epoc
EA201201343A1 (ru) Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а
ATE538100T1 (de) Aminotetrahydroindazoloessigsäuren
CL2011000425A1 (es) Compuestos derivados de heteroariloxi amidas del acido benzoico sustituido, inhibidores de map-quinasa p38; procedimiento de preparacion de los compuestos; composicion farmaceutica; procedimiento para preparar dicha composicion; y uso en el tratamiento de enfermedades de las vias aereas como epoc y asma.
CO6321136A2 (es) Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p)
CR20130102A (es) Imidazopiridazinas sustituidas
UY32848A (es) Compuestos heterocíclicos de oxima
CO6541540A2 (es) Derivados de ácido carboxílico sustituidos con acilamino y su uso como productos farmacéuticos
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
ECSP11011011A (es) Derivados de acido 1-amino-2-ciclobutiletilborónico
PA8825301A1 (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino y su uso como productos farmaceuticos
UY31198A1 (es) Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones.
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
AR082443A1 (es) Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
UY31922A (es) Compuestos

Legal Events

Date Code Title Description
FG Application granted